all report title image
  • Published In : Jul 2026
  • Code : CMI4513
  • Pages : 258
  • Formats :
      Excel/PDF
  • Industry : Pharmaceutical

In myelodysplastic syndrome (MDS), some of the blood forming cells in bone marrow become abnormal and have problems in forming new and mature blood cells. The immature blood cells called as blasts get stored in the bone marrow and blood, and obstruct the natural function of the hematological system, which results in depletion of healthy red blood cells, platelets, and white blood cells. It is usually observed in geriatric population and more often in older men compared to women. For instance, according to the American Society of Clinical Oncology (ASCO), age plays an important role in the occurrence of myelodysplastic syndrome, as most of the people diagnosed with the disease are of age 65 and older. 

Moreover, increasing possibility of MDS to further progress into rapidly growing cancer of bone marrow cells called acute myeloid leukemia (AML), leads to increasing efforts by key players develop highly effective therapies for MDS treatment. Furthermore, rising awareness about MDS and its symptoms with advanced methods and techniques for early diagnosis and treatment for various forms of the MDS is expected to drive the market growth over the forecast period. Increased understanding of the pathology of the syndrome is directing the research towards developing more specialized and symptom based treatments with effective costs, so that MDS patients can avail these benefits.

Market Dynamics

The increasing prevalence of MDS is expected to drive the demand of drugs used for the treatment of MDS, thereby expected to drive the U.S., Europe, and China myelodysplastic syndrome treatment market growth over the forecast period. Incidence rate for myelodysplastic syndrome has witnessed an increase in the last few years as the average population is ageing every consecutive year. For instance, according to the American Cancer Society report 2018, over 10,000 new cases of MDS occur in the U.S. every year, which is expected to boost the market growth.

Key features of the study

  • This report provides in-depth analysis of the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and Strategies
  • Key companies covered as a part of this study include Bristol Myers Squibb, Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Limited, Cipla Limited, Acceleron Pharma, Inc., Onconova Therapeutics, Inc., Aprea Therapeutics, Geron, Fibrogen, Inc., Jazz Pharmaceuticals, AbbVie Inc., Lixte Biotechnology Holdings, Inc., Gilead Sciences, CrystalGenomics, Inc., ALX Oncology Inc., and Keros Therapeutics.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market

Market Segmentation

  • By Drug (Revenue, USD Bn, 2021-2033)
    • Lenalidomide
    • Decitabine
    • Azacitidine
    • Luspatercept
    • Phase 3 Drugs
  • By Route of Administration (Revenue, USD Bn, 2021-2033)
    • Injection
    • Oral
  • By Distribution Channel (Revenue, USD Bn, 2021-2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region (Revenue, USD Bn, 2021-2033)
    • U.S.
    • Europe
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
    • China
  • Key Players
    • Bristol Myers Squibb
    • Otsuka Pharmaceutical Co., Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries Limited
    • Cipla Limited
    • Acceleron Pharma, Inc.
    • Onconova Therapeutics, Inc.
    • Aprea Therapeutics
    • Geron
    • Fibrogen, Inc.
    • Jazz Pharmaceuticals
    • AbbVie Inc.
    • Lixte Biotechnology Holdings, Inc.
    • Gilead Sciences
    • CrystalGenomics, Inc.
    • ALX Oncology Inc.
    • Keros Therapeutics

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug
      • Market Snapshot, By Route of Administration
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region/Country
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Disease Type Approval
    • Collaboration/Merge/Acquisition
    • Regulatory Landscape
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Epidemiology
    • Robust Pipeline Analysis
  4. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Drug, 2021 – 2033, (USD Billion)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022– 2033
      • Segment Trends
    • Lenalidomide
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
    • Decitabine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
    • Azacitidine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
    • Luspatercept
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
    • Phase 3 Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  5. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Route of Administration, 2021 – 2033, (USD Billion)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022– 2033
      • Segment Trends
    • Injection
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  6. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Distribution Channel, 2021 – 2033, (USD Billion)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022– 2033
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  7. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Region/Country, 2021 – 2033, (USD Billion)
    • Introduction
      • Market Share Analysis, By Region/Country, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, For Region/Country, 2022–2033
      • Region/Country Trends
    • U.S.
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • China
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
    • Company Profile
      • Bristol Myers Squibb
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Otsuka Pharmaceutical Co., Ltd.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Mylan N.V.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Reddy's Laboratories Ltd.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Sun Pharmaceutical Industries Limited
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Cipla Limited
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Acceleron Pharma, Inc.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Onconova Therapeutics, Inc.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Aprea Therapeutics
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Geron
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Fibrogen, Inc.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Jazz Pharmaceuticals
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • AbbVie Inc.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Lixte Biotechnology Holdings, Inc.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Gilead Sciences
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • CrystalGenomics, Inc.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • ALX Oncology Inc.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Keros Therapeutics
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About Us

View Our Licence Options

  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2026 Coherent Market Insights Pvt Ltd. All Rights Reserved.